Exact Sciences

497 articles about Exact Sciences

• Exact Sciences to participate in June 2023 investor conferences

  6/1/2023

  Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, announced that company management will participate in the following conferences and invited investors to participate by webcast.

• Exact Sciences Earns 2023 Great Place to Work® Certification™

  6/1/2023

  Exact Sciences Corp. announced that the company has been certified as a 2023 Great Place To Work® for the fifth consecutive year.

• Exact Sciences Presents New Long-Term Patient Outcomes in Multi-Cancer Early Detection and Breast Cancer Recurrence Testing at ASCO® 2023

  5/26/2023

  Exact Sciences Corp. announced that it will present 15 abstracts at the American Society of Clinical Oncology® Annual Meeting 2023, June 2-6, in Chicago, Illinois.

• EXACT SCIENCES AWARDS GRANTS TO 18 ORGANIZATIONS FOCUSED ON INCREASING COLORECTAL CANCER SCREENINGS

  5/17/2023

  Exact Sciences announced today that it awarded $1.1 million to 18 organizations through its Funding Opportunities for CRC Screening Uptake Strategies (FOCUS) Program.

• Exact Sciences Extends Leadership in Colorectal Cancer Screening with New Data Presented at Digestive Disease Week® Annual Meeting

  5/9/2023

  Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, presented new data supporting the company's research and innovation in colorectal cancer during Digestive Disease Week® 2023, May 6-9 in Chicago, Illinois.

• Exact Sciences Announces First Quarter 2023 Results

  5/9/2023

  Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, announced that the company generated revenue of $602.5 million for the first quarter ended March 31, 2023, compared to $486.6 million for the same period of 2022.

• Exact Sciences to participate in May 2023 investor conference

  5/1/2023

  Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, announced that company management will participate in the following conference and invited investors to participate by webcast.

• Exact Sciences schedules first quarter 2023 earnings call

  4/10/2023

  Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, announced that the company plans to release its first quarter 2023 financial results after the close of the U.S. financial markets on May 9, 2023.

• Exact Sciences to participate in March investor conferences - February 22, 2023

  2/22/2023

  Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast.

• Exact Sciences Announces Fourth Quarter 2022 Results

  2/21/2023

  Exact Sciences Corp. announced that the company generated revenue of $553.0 million for the fourth quarter of 2022 and $2,084.3 million for the full year of 2022, both ended Dec. 31, 2022.

• Exact Sciences Launches OncoExTra™ Cancer Therapy Selection Test in the U.S.

  2/7/2023

  Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the launch of the OncoExTra™ therapy selection test in the United States.

• Exact Sciences schedules fourth quarter 2022 earnings call

  2/1/2023

  Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its fourth quarter 2022 financial results after the close of the U.S. financial markets on February 21, 2023.

• Exact Sciences Announces Preliminary Fourth Quarter 2022 Results

  1/8/2023

  Exact Sciences Corp. announced that the company expects to report revenue between $550.7 million and $552.7 million for the fourth quarter ended Dec. 31, 2022.

• Exact Sciences to participate in J.P. Morgan Healthcare Conference 2023

  1/3/2023

  Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, announced that company management will participate in the following conference and invited investors to participate by webcast.

• Exact Sciences Presents First Time Data Detailing Ability to Predict Radiation Therapy Benefit in Breast Cancer Patients

  12/9/2022

  Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today shared initial clinical validation data for its breast cancer radiation signature, Profile for the Omission of Local Adjuvant Radiotherapy (POLAR), at the 2022 San Antonio Breast Cancer Symposium® (SABCS®).

• Exact Sciences Highlights the Impact of Precision Oncology Portfolio on Breast Cancer Treatment with 10 New Data Presentations at SABCS® 2022

  12/6/2022

   Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that new data presentations supporting the clinical value of its Precision Oncology portfolio will be shared in ten abstracts and three presentations at the 2022 San Antonio Breast Cancer Symposium® (SABCS®).

• Exact Sciences Announces Third Quarter 2022 Results

  11/3/2022

  Exact Sciences Corp. announced that the company generated revenue of $523 million for the third quarter ended September 30, 2022, compared to $456 million for the same period of 2021.

• Exact Sciences to participate in November 2022 investor conferences

  11/1/2022

  Exact Sciences Corp. announced that company management will participate in the following conferences and invited investors to participate by webcast.

• Exact Sciences Expands Leadership in Colorectal Cancer Screening with New Data Presented at the American College of Gastroenterology 2022 Annual Meeting

  10/24/2022

  Exact Sciences Corp. today announced the company will present new data supporting the positive impact of Cologuard® as a colorectal cancer screening tool during the American College of Gastroenterology (ACG) Annual Meeting, being held October 21-26, 2022.

• Exact Sciences schedules third quarter 2022 earnings call

  10/10/2022

  Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, announced that the company plans to release its third quarter 2022 financial results after the close of the U.S. financial markets on November 3, 2022.